Navigation Links
The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
Date:10/21/2010

BURLINGTON, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, the epilepsy drug market will remain relatively flat, increasing from $2.8 billion in 2009 to $2.9 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Epilepsy forecast a decline in overall sales through 2014 due to generic erosion, specifically within the second-generation antiepileptic drug (AED) class, which will lose approximately $400 million by 2014. Generic erosion within the epilepsy market remains relatively conservative but several popular second-generation AEDs will contend with strong generic competition over the next several years. Nevertheless, the market will recover as a result of uptake of both currently-marketed and emerging higher-priced third-generation AEDs.

"Through 2019, the majority of AEDs will be generically available, creating negative pressure on market growth," said Decision Resources Analyst Nadja Rozovsky, Ph.D. "However, emerging agents, combined with greater uptake of the already-available and mostly branded third-generation AEDs, will temper the impact of generic AEDs, and the market will recover by 2019."

The findings reveal that levetiracetam (UCB's Keppra/Keppra XR, generics) is the current market leader in epilepsy. Driven by its preferred use as both a first-line adjunctive therapy and increasingly as first-line monotherapy, levetiracetam will continue to lead the market in 2019 with approximately $540 million in major-market sales.

The continued uptake of current third-generation AEDs—particularly UCB's Vimpat and Sunovion/Bial/Eisai's Zebinix—and uptake of the emerging AEDs UCB's Rikelta, Valeant/GlaxoSmithKline's Potiga and Eisai's perampanel will offer alternative therapeutic options as adjunctive agents, according to the findings. Because these drugs will be used in later lines of adjunctive treatment and compete with established AEDs, however, they will experience only moderate uptake and earn modest sales.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Announces Epilepsy Technology Agreements
2. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
4. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
5. FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
6. Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
7. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
8. Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment
9. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
10. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
11. Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... research provides evidence that an old drug may provide relief ... today that will be presented at the American Academy ... , April 22 to 28, 2017. ... oral drug levodopa has long been considered the gold standard, ... progresses, the effects of the medication can partially wear off ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... compliance and credentialing solutions, today announced that Kyle Allain has joined the company ... Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... individuals with HIV because it is not known to have significant interactions with ... effects to both lower cholesterol levels and dampen inflammation in the bloodstream. , ...
(Date:4/24/2017)... ... 24, 2017 , ... A new global study of approximately ... well-being has seriously declined. "When disenfranchised youth from the heart of our countries, ... to turn the historic multi-ethnic and multi-religious powerhouses of the Middle East back ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
(Date:4/23/2017)... ... April 23, 2017 , ... ... services announced the achievement of Cisco Select certification and SMB specialization. Altura ... States. , In earning the Select Certification, Altura fulfilled the training ...
Breaking Medicine News(10 mins):